KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Pfizer (PFE) over the last 17 years, with Q2 2025 value amounting to $3.8 billion.

  • Pfizer's Long-Term Debt Repayments rose 27500.0% to $3.8 billion in Q2 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $2.2 billion for FY2024, which is 1241.73% down from last year.
  • According to the latest figures from Q2 2025, Pfizer's Long-Term Debt Repayments is $3.8 billion, which was up 27500.0% from $2.2 billion recorded in Q3 2024.
  • In the past 5 years, Pfizer's Long-Term Debt Repayments registered a high of $3.8 billion during Q2 2025, and its lowest value of $269.0 million during Q2 2023.
  • Moreover, its 5-year median value for Long-Term Debt Repayments was $1.3 billion (2023), whereas its average is $1.5 billion.
  • Per our database at Business Quant, Pfizer's Long-Term Debt Repayments crashed by 8328.15% in 2023 and then skyrocketed by 36468.4% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Long-Term Debt Repayments stood at $1.0 billion in 2021, then surged by 60.74% to $1.6 billion in 2022, then decreased by 19.2% to $1.3 billion in 2023, then skyrocketed by 73.08% to $2.2 billion in 2024, then surged by 66.67% to $3.8 billion in 2025.
  • Its Long-Term Debt Repayments stands at $3.8 billion for Q2 2025, versus $2.2 billion for Q3 2024 and $1.0 billion for Q2 2024.